IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders - IGC Pharma, INC.

Press

Releases

June 9, 2022

IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

Related Posts

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025

IGC Pharma Welcomes Strategic Investment from Advisors

April 24, 2025

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs

April 21, 2025

CEO Update

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025

IGC Pharma Welcomes Strategic Investment from Advisors

April 24, 2025